A Multicenter, Randomized, Double Blind, Placebo Controlled, Proof of Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Weekly Subcutaneous MLN1202, in Improving Diabetic Nephropathy in Subjects With Macroalbuminuria
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Plozalizumab (Primary)
- Indications Diabetic nephropathies
- Focus Proof of concept; Therapeutic Use
- Sponsors Takeda
- 22 Sep 2017 Planned End Date changed from 1 Aug 2017 to 17 Nov 2015.
- 22 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 17 Nov 2015.
- 22 Sep 2017 Planned initiation date changed from 1 Apr 2016 to 20 May 2015.